Biotherapy Services Limited

 

Rapidly improving the lives of patients with complex and chronic wounds

By harnessing the body’s ability to heal itself, autologous biological therapies such as the proprietary RAPID™ Biodynamic Haematogel, use concentrated platelets derived from the patient’s own blood, which are activated by autologous thrombin to release growth factors, cell signallers and proteins that work at a cellular level to stimulate the patient’s own healing process.

Specialist Pharmaceutical Biotech Company

Biotherapy Services Ltd. is a specialist pharmaceutical biotech company. We use state-of-the-art technology and patented proprietary processes, working to GMP (Good Manufacturing Practice) pharmaceutical manufacturing standards, to produce a range of clinically safe and effective autologous biotherapies for a broad range of clinical conditions.

Our RAPID™ Biodynamic Haematogel wound care treatment has been defined by the MHRA as the first-in-world, first-in-class wound care treatment, classified as a medicine. 

The MHRA have approved the commencement of the  RAPID-1 Diabetic Foot Ulcer Trial ISRCTN55474813  at the The Royal London Hospital, Barts Health NHS Trust.

For further information please contact us

RAPID™ Biodynamic Haematogel

The company is developing the RAPID™ Biodynamic Haematogel wound treatment for use in the management of complex and slow healing complex wounds such as diabetic foot ulcers and pressure sores.

Who are Biotherapy Services Ltd?

 

Biotherapy Services Ltd. are a multidisciplinary team of clinicians, scientists, pharmacists and healthcare professionals focused on the delivery of safe and effective autologous biotherapies for a range of clinical applications. Autologous biotherapies enhance your own bodies wound healing and tissue regeneration capabilities.

We provide GMP (Good Manufacturing Practice) pharmaceutical standard services to support clinical specialists in the use of novel autologous biotherapies. Our particular focus is wound healing, tissue regeneration, using stem cells derived from autologous fat grafts and growth factors from cPRP.

Concentrated platelet-rich plasma (cPRP) is an autologous product derived from whole blood through the process of centrifugation and cellular fractionation. Autologous cPRP has been shown to be safe and effective in promoting the natural processes of wound healing, soft tissue regeneration, bone and cartilage reformation.

Learn more about the RAPID 1DFU trial